Andrade JG, Champagne J, Dubuc M, et al. - In this multicenter, randomized, single-blinded trial, researchers assessed advanced generation ablation technologies with regard to their efficacy in reducing arrhythmia recurrence after atrial fibrillation (AF) ablation. Participants were 346 patients with drug-refractory paroxysmal AF who were randomly allocated to contactforce guided RF ablation (CF-RF ablation, 115), 4-minute cryoballoon ablation (CRYO-4, 115), or 2-minute cryoballoon ablation (CRYO-2, 116). These individuals were observed for 12 months. With CF-RF, CRYO-4, and CRYO-2, the estimated one-year freedom from atrial tachyarrhythmia (defined by continuous rhythm monitoring) was 53.9%, 52.2%, and 51.7%, respectively, and one-year freedom from symptomatic atrial tachyarrhythmia (defined by continuous rhythm monitoring) was estimated to be 79.1%, 78.2%, and 73.3%, respectively. Findings revealed that one-year efficacy was not different, which was 53% by time to first recurrence, when contact-force RF ablation and two different regimens of cryoballoon ablation were used and these regimens resulted in > 98% burden reduction as evaluated by continuous cardiac rhythm monitoring.